FDA approves FET-PET agent for glioma
The radioactive diagnostic drug is indicated in patients aged 1 month or older and is used in conjunction with other diagnostic evaluations.
By
Kathryn Wighton
September 14, 2026
Clinical Scorecard: FDA approves FET-PET agent for glioma
At a Glance
Category Detail
Condition Glioma Key Mechanisms Targets L-type amino acid transporters 1 and 2 for PET imaging. Target Population Adult and pediatric patients aged 1 month or older. Care Setting Positron emission tomography imaging.
Key Highlights
Remove or source the claim about safety evaluated in 382 patients. Guideline-Based Recommendations
Diagnosis
FET-PET imaging is recommended for differentiating recurrent or progressive glioma from treatment-related changes. Management
Interpretation of PET results should incorporate histopathology, cross-sectional imaging, and clinical history. Monitoring & Follow-up
Monitor for potential side effects such as headache, nausea, and injection-site reactions. Risks
Cumulative radiation exposure associated with increased risk of cancer. Patient & Prescribing Data
Patients with gliomas, including adults and pediatric patients.
Floretyrosine F 18 is administered intravenously and allows PET detection of emitted energy.
Clinical Best Practices
Use FET-PET imaging in conjunction with other diagnostic modalities. Be aware of the potential for false-positive or false-negative interpretations. Related Resources & Content
